{{Short description|Pharmaceutical drug used to treat blood clots}} {{Drugbox | verifiedrevid = 457131584 | drug_name = Anistreplase | IUPAC_name = <!--Clinical data --> | tradename = Eminase | Drugs.com = {{drugs.com|CONS|anistreplase}} | pregnancy_category = | legal_status = | routes_of_administration = <!--Pharmacokinetic data --> | bioavailability = | protein_bound = | metabolism = | elimination_half-life = 90 minutes <!--Identifiers -->| CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 81669-57-0 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 5O8V541HJ6 | ATC_prefix = B01 | ATC_suffix = AD03 | ATC_supplemental = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB00029 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D02947 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = none <!--Chemical data -->| molecular_weight = approx. 131 kg/mol }} '''Anistreplase''' is a thrombolytic drug. It is also known as '''anisoylated plasminogen streptokinase activator complex''' (APSAC). As a thrombolytic drug, it is used to treat blood clots in emergency situations.
== Uses == Anistreplase is used to treat blood clots in emergency situations such as myocardial infarction.<ref name="pmid8563585">{{cite journal|author=Rawles J|date=27 January 1996|title=Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)|url=https://www.bmj.com/content/312/7025/212.full|journal=British Medical Journal|volume=312|issue=7025|pages=212–5|doi=10.1136/bmj.312.7025.212|pmc=2350007|pmid=8563585}}</ref> Early treatment gives better outcomes.<ref name="pmid8563585" />
== History == Anistreplase has been developed by Beecham under the brand name Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC) after its components.<ref name="pmid8563585" /><ref name="pmid7612317">{{cite journal|vauthors=Hannaford P, Vincent R, Ferry S, Hirsch S, Kay C|date=April 1995|title=Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners|journal=Br J Gen Pract|volume=45|issue=393|pages=175–9|pmc=1239197|pmid=7612317}}</ref><ref name="pmid8289038">{{cite journal|vauthors=Rawles J, Light J|date=October 1993|title=Loss of quality adjusted days as a trial endpoint: effect of early thrombolytic treatment in suspected myocardial infarction. Grampion Region Early Anistreplase Trial (GREAT)|journal=J Epidemiol Community Health|volume=47|issue=5|pages=377–381|doi=10.1136/jech.47.5.377|pmc=1059832|pmid=8289038}}</ref>
== References == {{reflist}}
{{Antithrombotics}}
Category:Antithrombotic enzymes Category:Fibrinolytic enzymes {{blood-drug-stub}}